Revenue · 2011–2025
Biomarin Pharmaceutical revenue
$3.2B+12.9% · FY2025
Biomarin Pharmaceutical (BMRN) reported $3.2B in revenue for fiscal 2025, +12.9% year on year.
| Fiscal year | Revenue | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $3.2B | +12.9% | Open → |
| FY20242024-12-31 | $2.9B | +18.0% | Open → |
| FY20232023-12-31 | $2.4B | +15.4% | Open → |
| FY20222022-12-31 | $2.1B | +13.5% | Open → |
| FY20212021-12-31 | $1.8B | −0.8% | Open → |
| FY20202020-12-31 | $1.9B | +9.2% | Open → |
| FY20192019-12-31 | $1.7B | +14.3% | Open → |
| FY20182018-12-31 | $1.5B | +13.5% | Open → |
| FY20172017-12-31 | $1.3B | +17.6% | Open → |
| FY20162016-12-31 | $1.1B | +25.5% | Open → |
| FY20152015-12-31 | $890M | +18.8% | Open → |
| FY20142014-12-31 | $749M | +36.6% | Open → |
| FY20132013-12-31 | $548M | +9.5% | Open → |
| FY20122012-12-31 | $501M | +13.5% | Open → |
| FY20112011-12-31 | $441M | — | Open → |
Revenue — Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +15.3%
Revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Biomarin Pharmaceutical revenue |url=https://companiesranked.com/en/company/biomarin-pharmaceutical/revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Biomarin Pharmaceutical revenue. CompaniesRanked. https://companiesranked.com/en/company/biomarin-pharmaceutical/revenueBibTeX
@misc{companiesranked-en-company-biomarin-pharmaceutical-revenue-2026,
author = {{CompaniesRanked}},
title = {{Biomarin Pharmaceutical revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/biomarin-pharmaceutical/revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001048477-26-000004 · February 26, 2026
{{cite web |title=Biomarin Pharmaceutical revenue — 10-K (0001048477-26-000004) |url=https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.